for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

298.57USD

Change

0.08(+0.03%)

Volume

68,153

Today's Range

298.57

 - 

303.94

52 Week Range

223.26

 - 

468.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
298.49
Open
300.97
Volume
68,153
3M AVG Volume
25.79
Today's High
303.94
Today's Low
298.57
52 Week High
468.35
52 Week Low
223.26
Shares Out (MIL)
150.55
Market Cap (MIL)
44,484.99
Forward P/E
16.07
Dividend (Yield %)
--

Next Event

Biogen Inc Investor Day

Latest Developments

More

FDA Approves Samsung Bioepis And Biogen’s BYOOVIZ, LUCENTIS Biosimilar

Biogen Reports Positive Topline Results From Phase 2 Convey Study In Small Fiber Neuropathy

Berkshire Hathaway Dissolves Share Stake In Biogen and Axalta Coating Systems

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

CAMBRIDGE, MA

02142-1031

United States

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Michael R. McDonnell

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.26 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

13.5K

2019

14.4K

2020

13.4K

2021(E)

10.8K
EPS (USD)

2018

26.200

2019

33.570

2020

33.700

2021(E)

18.676
Price To Earnings (TTM)
23.94
Price To Sales (TTM)
3.80
Price To Book (MRQ)
4.14
Price To Cash Flow (TTM)
15.26
Total Debt To Equity (MRQ)
67.61
LT Debt To Equity (MRQ)
67.61
Return on Investment (TTM)
11.56
Return on Equity (TTM)
9.89

Latest News

Latest News

U.S. FDA approves first biosimilar rival to Roche's blockbuster eye drug

The U.S. Food and Drug Administration on Monday approved South Korean drugmaker Samsung Bioepis Co Ltd and Biogen Inc's biosimilar rival to Roche Holding AG's blockbuster eye drug, Lucentis.

U.S. Congress seeks information from FDA on approval of Biogen's Alzheimer's drug

U.S. lawmakers have requested data and documents from the Food and Drug Administration (FDA) related to its accelerated approval of Biogen Inc's new Alzheimer's drug, mounting further pressure on the agency that has come under fire for clearing the drug.

Biogen provides free Aduhelm as U.S. clinics await Medicare payment

Biogen Inc is providing its controversial and expensive new Alzheimer's drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the situation, including a doctor treating patients with the drug.

Buffett's Berkshire sheds Axalta, Biogen; buys Organon

Warren Buffett's Berkshire Hathaway Inc said on Monday it has shed its holdings of drugmaker Biogen Inc and paint maker Axalta Coating Systems Ltd , while taking a new stake in another pharmaceutical company, Organon & Co.

U.S. Veterans Health Administration turns down Biogen Alzheimer's drug

The U.S. Veterans Health Administration (VHA) will not include Aduhelm, the $56,000-a-year Alzheimer's drug made by Biogen Inc and Eisai Co Ltd, on its list of approved drugs due to a lack of evidence that it is effective as well as safety concerns, the agency said on Wednesday...

Federal investigators to review FDA's "accelerated pathway" over Alzheimer's drug approval

An independent federal review has been launched into the U.S. Food & drug Administration's accelerated approval pathway using which the agency approved Biogen Inc's Alzheimer's treatment Aduhelm.

Eli Lilly bets on Alzheimer's disease drug data as it chases Biogen

Eli Lilly and Co said on Tuesday it plans to seek U.S. approval for its experimental Alzheimer's disease drug by year end and believes the treatment could be favored by doctors once it becomes available to patients.

Biogen, Eisai report design of real-world study of Alzheimer's treatment

Biogen Inc and partner Eisai Co Ltd on Thursday revealed the design of an upcoming study of their controversial Alzheimer's treatment, Aduhelm.

Biogen withdrew Aduhelm paper after JAMA asked for edits - Axios

Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA, Axios reported on Tuesday, citing two sources familiar with the matter.

Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage

(This Jul.21 story fixes name of Tufts Medical Center in paragraph 18 (removes word "University"))

Biogen says uptake on new Alzheimer's drug slower than expected

Biogen Inc on Thursday said getting hospitals and clinics to use its new Alzheimer's disease drug Aduhelm and insurers to reimburse it has been slower than it expected, as controversy mounts over the U.S. Food and Drug Administration's approval process for the treatment.

Biogen profit tumbles 71% on rising competition to multiple sclerosis drug

Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

Anthem still determining coverage policy for Biogen Alzheimer's drug

Anthem Inc said on Wednesday it was closely watching for guidance from the U.S. Food and Drug Administration and all available clinical evidence on Biogen Inc's Aduhelm to determine its coverage policy on the newly approved Alzheimer's drug.

Former FDA adviser calls for wider probe into Biogen Alzheimer's drug approval

A federal probe of the U.S. Food and Drug Administration's approval of a controversial new Alzheimer's disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said on Tuesday.

Biogen Alzheimer's drug hits roadblocks with some hospitals, insurers

Biogen Inc's Alzheimer's drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare.

UnitedHealth seeks more clarity on Biogen's $56,000 Alzheimer's drug coverage

UnitedHealth Group Inc said it needed more time to determine its coverage policy for Biogen's recently approved $56,000 Alzheimer's disease drug Aduhelm that is expected to raise costs for the U.S. government Medicare program.

Biogen Alzheimer's drug hits roadblocks with some hospitals, insurers

The rollout of Biogen Inc's Alzheimer's drug is hitting new roadblocks as some large hospitals decide not to use it and many health insurers await coverage terms from Medicare, the U.S. health plan for people aged 65 and older, before setting their own policies.

UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO

UnitedHealth Group Inc said on Thursday that it is still developing its coverage policy for Biogen Inc.'s Alzheimer's drug Aduhelm, which was recently approved by the U.S. regulator.

U.S. review of Biogen Alzheimer's drug could have been handled better -FDA chief

The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc's Alzheimer's drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat.

U.S. review of Biogen Alzheimer's drug could have been handled differently -FDA chief

The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc's Alzheimer's drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up